How should we assess and manage an 81‑year‑old woman with recent pulmonary embolism on apixaban, iron‑deficiency anemia treated with oral iron, prior transient ischemic attack, hypothyroidism, hyperlipidemia, diverticulosis, and depression who presents with one episode of melena, one episode of hematemesis, and hematochezia, with CTA showing mild cecal angiectasias and diverticulosis, colonoscopy deferred, now having severe normocytic anemia with hemoglobin around 8.6 g/dL, an elevated BUN‑to‑creatinine ratio, and a slightly elevated INR?

Assessment and Plan for GI Consultation: 81-Year-Old Female with Melena, Hematemesis, and Hematochezia on Apixaban

Clinical Assessment

This patient requires immediate cessation of apixaban and initiation of intravenous iron therapy, with urgent upper endoscopy once hemoglobin stabilizes above 8 g/dL and coagulopathy resolves.

Current Hemodynamic Status

• Hemoglobin dropped from 9.1 to 7.6 g/dL, representing acute blood loss superimposed on chronic iron-deficiency anemia 1
• BUN/Cr ratio of 67 (49/0.73) strongly suggests upper GI bleeding as the primary source 1
• INR 1.44 indicates residual anticoagulant effect from apixaban that must resolve before endoscopy 2
• Patient is hemodynamically stable (no shock, no acute coronary syndrome mentioned), so restrictive transfusion threshold of 7 g/dL applies 1, 3

Bleeding Source Localization

• Black emesis (hematemesis) definitively localizes bleeding to upper GI tract 1
• Melena confirms upper GI source; the 500 mL of blood needed to produce melena indicates significant hemorrhage 1
• Prior hematochezia during recent hospitalization was likely from brisk upper GI bleeding (blood transit time <14 hours produces hematochezia even from upper sources) 1
• CTA findings of cecal angiectasias and diverticulosis are incidental—they do not explain hematemesis 1

Underlying Iron-Deficiency Anemia

• Baseline hemoglobin 8.5 g/dL with MCV 93 indicates normocytic anemia masking iron deficiency 1, 3
• In elderly patients on oral iron with persistent anemia, inadequate absorption or ongoing occult blood loss is the cause 1, 3
• The combination of chronic IDA and acute upper GI bleeding mandates investigation for gastric pathology (gastritis, ulcer, malignancy) 1

---

Immediate Management Plan

1. Anticoagulation Management

• Hold apixaban immediately; do not resume until source control is achieved and hemoglobin is stable for ≥48 hours 2
• Apixaban has a half-life of 12 hours; INR will normalize within 24–48 hours without reversal agents 2
• Do not use bridging anticoagulation during the interruption—the PE is now 2–3 weeks old and stable 2
• Restart apixaban at 5 mg twice daily (standard PE treatment dose) only after endoscopic hemostasis is confirmed and hemoglobin remains stable ≥48 hours 2

2. Transfusion Decision

• Do not transfuse at hemoglobin 7.6 g/dL in a hemodynamically stable patient without active bleeding, chest pain, or altered mentation 1, 3
• Restrictive threshold of 7 g/dL is appropriate; transfusion at higher thresholds increases mortality in stable GI bleeding 1
• If hemoglobin drops below 7 g/dL or patient develops tachycardia >110, hypotension, chest pain, or dyspnea, transfuse 1 unit and reassess 1, 3
• Target hemoglobin 7–9 g/dL (not >9 g/dL) to minimize transfusion-related complications 1

3. Intravenous Iron Therapy

• Start IV iron immediately—do not wait for endoscopy or hemoglobin stabilization 1, 3
• Ferric carboxymaltose 1000 mg IV over 15 minutes as a single dose is the preferred regimen 1, 3
• IV iron will produce a clinically meaningful hemoglobin rise (≈2 g/dL) within 7–12 days, reducing transfusion need 1, 3
• Absolute indication for IV iron: active bleeding exceeding oral replacement capacity + baseline IDA + age >80 years 1, 3
• Administer in a monitored setting with resuscitation equipment available (anaphylaxis risk 0.6–0.7%) 1, 3

4. Endoscopic Evaluation

• Perform urgent upper endoscopy within 24 hours once INR normalizes (<1.5) and hemoglobin stabilizes 1
• Endoscopy is mandatory in an 81-year-old with hematemesis to exclude malignancy, even if bleeding stops 1
• Likely findings: peptic ulcer disease, gastritis, or gastric angiectasia (given history of AVMs elsewhere) 1
• Obtain gastric and duodenal biopsies to screen for Helicobacter pylori and assess for atrophic gastritis (given chronic IDA) 1, 3
• Do not perform colonoscopy at this time—the cecal findings on CTA are irrelevant to hematemesis 1

---

Long-Term Iron Repletion Strategy

After Acute Bleeding Resolves

• Continue oral ferrous sulfate 200 mg once daily (patient is already on oral iron) 1, 3
• Add vitamin C 500 mg with each iron dose to enhance absorption, especially critical given low baseline hemoglobin 1, 3
• Take iron on an empty stomach; if not tolerated, switch to ferrous fumarate or gluconate 1, 3
• Do not use multiple daily doses—once-daily dosing is superior due to hepcidin regulation 1, 3

Monitoring Protocol

• Recheck hemoglobin 4 weeks after IV iron; expect rise to ≈9.6 g/dL (2 g/dL increase) 1, 3
• Continue oral iron for 3 months after hemoglobin normalizes (total 6–7 months) to replenish stores 1, 3
• Monitor hemoglobin every 3 months for the first year, then annually 1, 3

If Oral Iron Fails

• Switch to IV iron every 3–6 months if ferritin remains <100 ng/mL or hemoglobin drops despite adherence 1, 3
• Repeat upper endoscopy if anemia recurs to exclude occult malignancy or rebleeding 1

---

Anticoagulation Resumption Strategy

Timing of Restart

• Resume apixaban 48–72 hours after endoscopic hemostasis if no high-risk stigmata (visible vessel, adherent clot) are found 2
• If high-risk ulcer is treated endoscopically, delay restart for 5–7 days and use high-dose PPI (pantoprazole 40 mg IV twice daily) 2
• Do not use heparin bridging—the PE is subacute and bridging increases rebleeding risk 2, 4

Dose Adjustment

• Apixaban 5 mg twice daily is the standard PE treatment dose for this patient 2
• Do not reduce to 2.5 mg twice daily—this dose is only for recurrence prevention after ≥6 months of full-dose therapy 2
• Patient does not meet criteria for dose reduction (age ≥80 + weight ≤60 kg + Cr ≥1.5); only 1 of 3 criteria is met (age 81) 2

Duration of Therapy

• Continue apixaban indefinitely for provoked PE (hip fracture + immobility) with ongoing risk factors (age, limited mobility) 2, 5
• After 6 months of 5 mg twice daily, consider reducing to 2.5 mg twice daily for long-term prevention if bleeding risk remains high 2
• Do not stop anticoagulation after 3–6 months—elderly patients with provoked PE have high recurrence rates 5

---

Special Considerations in This Patient

Balancing PE Recurrence vs. Bleeding Risk

• Anticoagulation is NOT contraindicated despite GI bleeding—the PE is life-threatening and requires treatment 1, 2
• Elderly patients with idiopathic or provoked PE benefit from long-term anticoagulation even with fall risk 5
• Source control (endoscopic therapy + PPI) is the key to safe anticoagulation resumption, not indefinite withholding 2

Addressing Chronic IDA

• Investigate for gastric pathology (atrophic gastritis, H. pylori, malignancy) as the cause of chronic IDA 1, 3
• Screen for celiac disease with tissue transglutaminase IgA if gastric workup is negative 1, 3
• Do not attribute IDA solely to dietary insufficiency in an 81-year-old—GI pathology is present until proven otherwise 1

Avoiding Common Pitfalls

• Do not continue oral iron alone after acute bleeding—IV iron is mandatory to rapidly correct severe anemia 1, 3
• Do not delay endoscopy beyond 24 hours in a patient with hematemesis and anticoagulation 1
• Do not restart apixaban before INR normalizes (<1.5)—residual anticoagulant effect increases rebleeding risk 2
• Do not stop iron therapy when hemoglobin normalizes—continue for 3 months to replenish stores 1, 3
• Do not perform colonoscopy to evaluate cecal angiectasias when hematemesis localizes bleeding to the upper GI tract 1

---

Summary Algorithm

1. Hold apixaban → Wait 24–48 hours for INR <1.5
2. Start IV ferric carboxymaltose 1000 mg immediately
3. Transfuse only if Hb <7 g/dL or hemodynamic instability
4. Urgent upper endoscopy within 24 hours → Treat bleeding source + biopsy for H. pylori
5. Resume apixaban 5 mg twice daily 48–72 hours post-hemostasis (or 5–7 days if high-risk ulcer)
6. Continue oral iron 200 mg + vitamin C 500 mg daily for 6–7 months
7. Recheck Hb at 4 weeks → Expect 2 g/dL rise from IV iron
8. Repeat endoscopy if anemia recurs despite adequate iron therapy